5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.74▲ | 6.47▲ | 6.49▲ | 6.60▲ | 6.42▲ |
MA10 | 6.54▲ | 6.45▲ | 6.59▲ | 6.30▲ | 6.25▲ |
MA20 | 6.45▲ | 6.60▲ | 6.56▲ | 6.23▲ | 6.03▲ |
MA50 | 6.63▲ | 6.32▲ | 6.25▲ | 6.06▲ | 6.30▲ |
MA100 | 6.45▲ | 6.22▲ | 6.30▲ | 5.93▲ | 6.67▲ |
MA200 | 6.28▲ | 6.20▲ | 6.13▲ | 6.10▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.080▲ | -0.010▼ | -0.012▼ | 0.071▲ | 0.130▲ |
RSI | 68.504▲ | 63.105▲ | 64.784▲ | 60.963▲ | 57.906▲ |
STOCH | 98.851▲ | 34.621 | 19.873▼ | 69.607 | 71.283 |
WILL %R | 0.000▲ | -34.286 | -34.286 | -23.529▲ | -19.370▲ |
CCI | 156.165▲ | 116.595▲ | 117.933▲ | 173.461▲ | 170.167▲ |
Thursday, July 24, 2025 05:15 AM
Coya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell function in patients with neurodegenerative disorders, announces the ...
|
Thursday, May 08, 2025 01:15 AM
HOUSTON, May 08, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg ...
|
Tuesday, April 29, 2025 02:40 AM
Coya Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for COYA's full-year earnings has moved 7.8% higher.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/08/25 | 6.895 | 6.90 | 6.895 | 6.90 | 57,119 |
25/08/25 | 7.15 | 7.30 | 6.14 | 6.50 | 416,908 |
22/08/25 | 6.71 | 6.89 | 6.49 | 6.86 | 94,939 |
21/08/25 | 6.15 | 6.68 | 6.05 | 6.59 | 109,492 |
20/08/25 | 5.93 | 6.19 | 5.89 | 6.15 | 42,411 |
19/08/25 | 6.09 | 6.1491 | 5.86 | 5.94 | 90,700 |
18/08/25 | 6.10 | 6.14 | 5.875 | 6.01 | 24,619 |
15/08/25 | 5.79 | 6.19 | 5.7031 | 6.15 | 23,808 |
14/08/25 | 6.19 | 6.28 | 5.60 | 5.685 | 89,796 |
13/08/25 | 6.14 | 6.25 | 5.95 | 6.20 | 38,717 |
|
|
||||
|
|
||||
|
|